N@N

Market Maker Surveillance Report. ASML, BKS, NBY, PIP, VRML, UGAZ, Losing Stocks With Lowest Price Friction For Thursday, Nove

November 29, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3997 companies with "abnormal" market making, 3566 companies with positive Friction Factors and 1897 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. ASML Holding NV (NASDAQ:ASML), Barnes & Noble Inc (NYSE:BKS), Novabay Pharmaceuticals Inc (AMEX:NBY), PharmAthene Inc (AMEX:PIP), Vermillion Inc (NASDAQ:VRML), (NYSE:UGAZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  ASML    $-14.350  -18.64%   1,233,838    39.80%    1,421,594    45.85%    -187,756     -131    
  BKS     $-1.790   -11.15%   1,694,847    29.30%    1,923,086    33.25%    -228,239     -1,275  
  NBY     $-0.160   -9.94%    72,787       24.67%    105,175      35.65%    -32,388      -2,024  
  PIP     $-0.150   -10.87%   141,634      36.33%    166,876      42.81%    -25,242      -1,683  
  VRML    $-0.220   -13.25%   288,609      42.09%    397,119      57.91%    -108,510     -4,932  
  UGAZ    $-4.180   -12.28%   226,659      29.64%    267,585      34.99%    -40,926      -98     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ASML with a dollar loss Thursday of $-14.35000 and a Friction Factor of -131 shares. That means that it only took 131 more shares of selling than buying to move ASML lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

ASML Holding NV (NASDAQ:ASML) - ASML Holding N.V., through its subsidiaries, engages in designing, manufacturing, marketing, and servicing semiconductor processing equipment used in the fabrication of integrated circuits. The company offers a portfolio of lithography systems for manufacturing semiconductors, integrated circuits, or chips. Its PAS 5500 product family comprises wafer steppers, and step and scan systems suitable for the i-line, krypton fluoride, and argon fluoride processing of wafers. The company also provides TWINSCAN, a dual-stage design system that allows wafer measurement. In addition, it offers Tachyon SMO, a source-mask optimization product that allows co-optimization of source and mask; and programmable illumination and BaseLiner scanner matching technology, which offers scanner stability optimization and stabilizes manufacturing process windows. The company operates principally in Japan, Korea, Singapore, Taiwan, Europe, and the United States. It has strategic alliance with Zeiss. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands..

Barnes & Noble Inc (NYSE:BKS) - Barnes & Noble, Inc., together with its subsidiaries, operates as a bookseller in the United States. The company provides access to books, magazines, newspapers, and other content across its multi-channel distribution platform. The company sells trade books, childrens books, eBooks, other digital content, eReaders and related accessories, bargain books, magazines, gifts, caf products and services, music, and movies, as well as mass market paperbacks, such as mystery, romance, science fiction, and other popular fiction direct to customers through its bookstores and Website, Barnes & Noble.com. It also offers textbooks and course-related materials, emblematic apparel and gifts, school and dorm supplies, and convenience and caf items on college and university campuses for students, faculty members, and campus administrators. In addition, the company publishes a range of non-fiction and illustrated books and kits in the categories of health and wellness, music and popular culture, food and wine, crafts and photography, puzzles and games, history and current affairs, and childrens books. As of May 1, 2010, it operated approximately 1,357 bookstores in 50 states, including 637 bookstores on college campuses and an ecommerce site. The company was founded in 1986 and is based in New York, New York..

Novabay Pharmaceuticals Inc (AMEX:NBY) - NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. The company is developing commercial opportunities for its portfolio of anti-infective Aganocide compounds in four healthcare markets, including dermatology, ophthalmology, urology, and hospital infections. Its lead product candidate, NVC-422, is used for the treatment of adenoviral conjunctivitis, a type of Pink Eye; killing of P. acne, the bacterium associated with inflamed acne lesions, and other known dermal pathogens; and treatment of uropathogens, including Proteus mirabilis, a gram-negative bacterium that can cause urinary catheter blockage and encrustation. The company is also developing NVC-101, an acidic composition of hypochlorous acid to promote wound healing, tissue repair, and tissue regeneration. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocide compounds in the eye, ear, and sinus infections, as well as for contact lens solutions; and with Galderma S.A. to develop and commercialize its Aganocide compounds in acne, impetigo, and other dermatological indications. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California..

PharmAthene Inc (AMEX:PIP) - PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine to protect against inhalation anthrax that has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax, which has completed Phase I clinical trial. The companys product candidates also include Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant plague vaccine comprising separate recombinant F1 (rF1) and V (rV) antigens produced in Escherichia coli, which completed three Phase I human clinical trials; and rPA anthrax vaccine, which does not require refrigeration. The companys customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize Valortim. PharmAthene, Inc. was founded in 2001 and is based in Annapolis, Maryland..

Vermillion Inc (NASDAQ:VRML) - Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and womens health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the OVA1 Test), which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests. Vermillion, Inc. primarily serves clinical reference laboratories. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is based in Fremont, California..

(NYSE:UGAZ) - .

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net